|
HS Code |
333134 |
| Name | Bromo - Thiazole |
| Chemical Formula | C3H2BrNS |
| Molar Mass | 162.02 g/mol |
| Appearance | Typically a solid or liquid (depending on substitution and conditions) |
| Odor | May have a characteristic, often pungent odor |
| Solubility In Water | Poorly soluble in water |
| Solubility In Organic Solvents | Soluble in common organic solvents like ethanol, dichloromethane |
| Melting Point | Varies based on specific isomer and substitution |
| Boiling Point | Varies based on specific isomer and substitution |
| Density | Varies based on specific isomer and conditions |
| Reactivity | Reactive towards nucleophiles due to the presence of bromine and the heterocyclic ring |
As an accredited Bromo-Thiazole factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 100g of Bromo - Thiazole packaged in a sealed, corrosion - resistant container. |
| Shipping | Bromo - Thiazole is shipped in sealed, corrosion - resistant containers. Adequate cushioning is used to prevent breakage. Shipments follow strict hazardous chemical regulations, ensuring safe transport by land or sea. |
| Storage | Bromo - Thiazole should be stored in a cool, dry, well - ventilated area, away from heat sources and ignition points. It should be kept in a tightly - sealed container to prevent leakage and exposure to air or moisture, which could potentially cause decomposition or reaction. Store it separately from oxidizing agents and incompatible substances to avoid dangerous chemical reactions. |
Halogen Exchange Reactivity Gradients in Thiamethoxam Precursor SynthesisFor the industrial manufacture of thiamethoxam (FAO Specification 717/2008), 2-bromo-5-methylthiazole serves as the foundational C-5 heterocycle. The critical pathway is a copper(I)-catalyzed halogen exchange to yield 2-chloro-5-methylthiazole, subsequently chlorinated at the methyl position with sulfuryl chloride. Formulation input ratio is tightly goverened: the exchange step uses 2-bromo-5-methylthiazole, spray-dried potassium fluoride (KF, ≤500 ppm H₂O), and cuprous iodide in a molar charge of 1 : 2.2 : 0.05 within anhydrous dimethylformamide. Process deviation beyond 1 : 2.0 fluoride leads to incomplete conversion; above 2.5, the generation of potassium bromide fines accelerates abrasion in centrifugal pumps. Regulatory compliance under EPA 40 CFR 180 and EU Regulation 396/2005 mandates a total brominated by-product limit below 0.1% w/w in the technical concentrate. Downstream, the 2-chloro-5-chloromethylthiazole is condensed with 3-methyl-4-nitroimino-1,3,5-oxadiazinane in acetonitrile at 45–50 °C to yield the active ingredient. On a 5000 L glass-lined reactor train, the narrow reaction exotherm—ΔT failure mode observed when jacket cooling fails to respond within 90 seconds—produces a dimeric impurity spike above 2%, irreversibly contaminating the batch. Terminal product types are 25% WG (water-dispersible granules) and 350 g/L FS (flowable concentrate for seed treatment).
In the production of orally administered cephalosporin prodrugs, 2-bromo-4-methylthiazole-5-acetic acid is converted to a mixed anhydride and condensed with 7-amino-3-(4-methylthiazol-5-yl)methyl-3-cephem-4-carboxylate. The active ester formulation ratio in the acylation vessel—typically a 3000 L stainless-steel reactor with retreated-blade agitator operating at 85 rpm—is 1.2 mol of the thiazole side-chain per 1.0 mol of the β-lactam nucleus. Charge sequencing is irreversible: the pre-cooled (−10 °C) nucleus slurry is dosed into the activated acid solution to prevent exothermic spikes exceeding 2 °C/min, which crosslink the cephem ring generating a Δ³-isomer burden above pharmacopoeial limits. Compliance follows ICH Q7 (Good Manufacturing Practice for Active Pharmaceutical Ingredients) and FDA 21 CFR Part 211, with residual bromine species controlled by a validated HPLC method (LOD 50 ppm). Production-scale experience documents an impurity RRT 1.34 reaching 0.82% when the median mixing time in the interface region of the half-pipe coil jacket exceeds 12 seconds—a condition alleviated by retrofitting with a tri-shaft baffle array. The crystallized sodium salt intermediate is dried in a 0.1 bar conical screw dryer to ≤0.5% LOD. Terminal products are film-coated tablets of cefditoren pivoxil (200 mg and 400 mg) and granules for oral suspension. Palladium-catalyzed cross-coupling of 2-bromothiazole with tri-n-butyl(1-ethoxyvinyl)tin at 0.95:1 molar ratio (bromide limiting to suppress organotin carryover) generates a ketone precursor that, after acid hydrolysis at pH 2.0–2.5 and vacuum fractional distillation, yields 2-acetylthiazole. This substance meets FEMA GRAS 3328 and JECFA 1041 specifications for flavoring preparations, with permitted carryover of inorganic bromide below 30 ppm. The downstream formulation of process flavors adds the ingredient at 0.02–5.0 ppm in the final food matrix, imparting nutty and roasted-meat notes. Equipment used is a 50 L glass-lined still coupled to a 12-inch Vigreux column; the heart cut is collected at 89–91 °C under 12 mmHg. Terminal product types are liquid flavor compounds for savory snacks and retorted soups. Donor–Acceptor Copolymer Bandgap Tuning via Thiazole MonomersOrganic field-effect transistor (OFET) fabrication utilizes the electron-deficient character of 2,5-dibromothiazole to construct alternating copolymers. Polycondensation with 5,5′-bis(trimethylstannyl)-2,2′-bithiophene proceeds via Stille coupling in anhydrous chlorobenzene under N₂ atmosphere at 130 °C for 48 h. The molecular-weight-critical stoichiometric ratio is 1 : 1.000; a deviation of only ±0.25 mol% shifts the number-average molecular weight (Mₙ) from 28 kDa (Ð ≈ 2.1) to below 12 kDa, rendering the film brittle. End-capping is performed with 2-tributylstannylthiophene and 2-bromothiophene sequentially. Manufacturing complies with RoHS 2011/65/EU for residual heavy metals, and tin content is analyzed per IEC 62321-5:2013. Processing hazards include the formation of a palladium black colloidal suspension if the P(o-tolyl)₃:Pd₂(dba)₃ ratio drops below 8 : 1, which shuts down chain extension. The polymer is purified by successive Soxhlet extraction with methanol, acetone, and hexane, then dissolved in chloroform and filtered through a 0.45 μm PTFE membrane. Terminal product forms are spin-coated semiconductor layers in bottom-gate top-contact OFETs with mobilities of 0.15–0.35 cm²/V·s.
When 2-Bromothiazole Replaces 2-Bromobenzothiazole in Asymmetric Cyanine Dye SynthesisFlow cytometry and qPCR detection systems employ asymmetric cyanine dyes wherein 2-bromothiazole is condensed with 1-methylquinolinium salts in methanol under basic conditions. The molar feed ratio of 2-bromothiazole to the quinolinium intermediate is 1.05 : 1 in the presence of 1.5 equivalents of triethylamine; the mixture is heated to 65 °C for 3 h to form the monomethine bridge. Substituting the traditional benzothiazole ring with thiazole blue-shifts the absorption maximum from ∼500 nm toward 475 nm, permitting multiplexed optical channels. Quality conformance abides by ISO 13485:2016 as a biochemical reagent, and palladium clearance is monitored via inductively coupled plasma mass spectrometry to <10 ppm. The raw dye is purified on a silica gel 60 Å column with a dichloromethane/methanol (9:1) mobile phase. Terminal product types are lyophilized powders for propidium iodide-alternative dead-cell stains and SYBR Green-complementary nucleic acid gel stains. |
Competitive Bromo-Thiazole prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
| Parameter | 2‑Bromothiazole | 2‑Chlorothiazole | 2‑Iodothiazole | 5‑Bromothiazole |
|---|---|---|---|---|
| CAS number | 3034-53-5 | 3034-52-4 | 3034-55-7 | 4175-77-3 |
| Molecular weight (g·mol⁻¹) | 163.99 | 119.55 | 210.99 | 163.99 |
| Boiling point (°C / mmHg) | 65–67 / 15 | 71–72 / 50 | 82–84 / 15 | 86–88 / 25 |
| Half‑wave potential E₁/₂ (V vs SCE)⁽¹⁾ | −1.87 | −2.12 | −1.54 | −2.03 |
| Relative rate Suzuki coupling⁽²⁾ with PhB(OH)₂, Pd(PPh₃)₄ | 1.00 (ref.) | 0.14 | 6.3 | 0.05 |
| Typical purity specification (GC area%) | ≥ 98.5 | ≥ 98.0 | ≥ 97.0 | ≥ 97.5 |
| ⁽¹⁾ Measured in DMF/0.1 M TBAPF₆ at a glassy carbon electrode, scan rate 100 mV·s⁻¹. ⁽²⁾ Rate normalized to 2‑bromothiazole; conditions: 1.0 mmol halide, 1.2 mmol boronic acid, 0.05 mol % Pd(PPh₃)₄, K₂CO₃ (2 equiv), THF‑H₂O 4:1, 60 °C, initial rates. | ||||